A detailed history of Rhumbline Advisers transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 26,591 shares of VRCA stock, worth $211,398. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,591
Previous 22,077 20.45%
Holding current value
$211,398
Previous $130,000 48.46%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$5.89 - $9.56 $26,587 - $43,153
4,514 Added 20.45%
26,591 $193,000
Q1 2024

May 09, 2024

SELL
$4.74 - $6.81 $1,474 - $2,117
-311 Reduced 1.39%
22,077 $130,000
Q4 2023

Feb 08, 2024

SELL
$2.93 - $7.32 $3,061 - $7,649
-1,045 Reduced 4.46%
22,388 $163,000
Q3 2023

Nov 09, 2023

BUY
$3.75 - $7.46 $10,931 - $21,745
2,915 Added 14.21%
23,433 $90,000
Q2 2023

Aug 08, 2023

BUY
$5.32 - $6.79 $109,155 - $139,317
20,518 New
20,518 $118,000
Q2 2022

Aug 11, 2022

SELL
$1.81 - $8.93 $23,111 - $114,027
-12,769 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$7.59 - $9.49 $4,394 - $5,494
-579 Reduced 4.34%
12,769 $104,000
Q4 2021

Feb 10, 2022

BUY
$9.1 - $13.36 $3,385 - $4,969
372 Added 2.87%
13,348 $122,000
Q3 2021

Nov 12, 2021

BUY
$9.55 - $13.96 $1,260 - $1,842
132 Added 1.03%
12,976 $162,000
Q2 2021

Aug 05, 2021

SELL
$9.77 - $15.33 $5,764 - $9,044
-590 Reduced 4.39%
12,844 $145,000
Q1 2021

May 06, 2021

SELL
$10.51 - $17.46 $6,936 - $11,523
-660 Reduced 4.68%
13,434 $204,000
Q4 2020

Feb 10, 2021

BUY
$7.41 - $12.63 $6,743 - $11,493
910 Added 6.9%
14,094 $162,000
Q3 2020

Nov 12, 2020

SELL
$6.16 - $10.3 $13,182 - $22,042
-2,140 Reduced 13.97%
13,184 $102,000
Q2 2020

Aug 13, 2020

SELL
$9.02 - $15.12 $18,067 - $30,285
-2,003 Reduced 11.56%
15,324 $169,000
Q1 2020

May 06, 2020

BUY
$7.14 - $16.86 $714 - $1,686
100 Added 0.58%
17,327 $189,000
Q4 2019

Feb 05, 2020

BUY
$13.08 - $17.43 $4,041 - $5,385
309 Added 1.83%
17,227 $274,000
Q3 2019

Oct 23, 2019

BUY
$8.65 - $14.81 $7,767 - $13,299
898 Added 5.61%
16,918 $250,000
Q2 2019

Aug 14, 2019

BUY
$7.1 - $11.62 $40,967 - $67,047
5,770 Added 56.29%
16,020 $186,000
Q1 2019

May 01, 2019

BUY
$7.95 - $14.07 $81,487 - $144,217
10,250 New
10,250 $111,000

Others Institutions Holding VRCA

About Verrica Pharmaceuticals Inc.


  • Ticker VRCA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,094,100
  • Market Cap $327M
  • Description
  • Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...
More about VRCA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.